The Successful Model of Collaboration between Academia and Corporation for Medical Industry in Taiwan – Case study: Center for Innovative Therapeutics Discovery, National Taiwan University
Date Issued
2014
Date
2014
Author(s)
Wang, Ya-Chun
Abstract
The collaboration and technical transfer between academic and industry are lack of successful case currently. Supposedly, the human capital, grants and resources invested from academic and RD institute should have the ability to provide a superior innovative new drug candidate for industry to develop in the second stage. This collaboration should help Taiwan’s biotech industry to stand out and meet the challenges in global market. The Center for Innovative Therapeutics Discovery (CITD), NTU has the vision, purpose and goal to establish the platform for long term development to be the bridge of new drug discovery and business development. The major tasks are two. First, CITD should establish the platform of core technology, core ability, core resources, and integration of resources for the discovery of innovative new drug. Second, CITD should be the bridge of academic and industry to establish the core technology and resources based on the needs of industry in Taiwan. How to screen the new drug leading compounds and train the professional skills for industry to use in the second stage should be the most important direction of CITD to push and promotion.
Based on the diseases and unmet clinical needs evaluation, CITD could establish the core technology, ability, and resource on the fields with the challenging strength and professional skill in Taiwan, not the fields of big pharmaceutical company’s focus. For example, the live diseases HBV, HCC are the major problem for Chinese to be treated. CITD can create a standardized model for the collaboration of academic and industry to become the successful model meeting the needs of industry on Taiwan based on its unique RD structure, strategies, and core technology.
Based on the diseases and unmet clinical needs evaluation, CITD could establish the core technology, ability, and resource on the fields with the challenging strength and professional skill in Taiwan, not the fields of big pharmaceutical company’s focus. For example, the live diseases HBV, HCC are the major problem for Chinese to be treated. CITD can create a standardized model for the collaboration of academic and industry to become the successful model meeting the needs of industry on Taiwan based on its unique RD structure, strategies, and core technology.
Subjects
產學合作
新藥產業
創新藥物
學術界研發成果
研發管理及激勵
SDGs
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-103-P00748031-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):611fb954aa206318755f1249a9c1b744